Curasight Achieves First Milestone in uTRACE PET Imaging with Curium

Curasight A/S (Curasight), a global leader in radiology, announced that it has achieved the first milestone in the development of Curasight's uTRACE PET imaging technology for the treatment of prostate cancer through an agreement with Curium Inc. This certification refers to the GMP manufacturing verification of the finished product. The $500,000 token is the first contract signed with Curium Inc. in May 2023. Under the terms of the agreement, Curasight will develop its proprietary uTRACE technology for use in prostate cancer, pending regulatory approval in the EU and US. Curium is responsible for business development and global marketing for uTRACE. Curasight can earn up to US$70 in development and marketing royalties, including double digit royalties on key market sales based on final sales.

"Achieving this milestone shows the strong progress we have made through our agreement with Curium, a world leader in nuclear medicine and a world expert in the development, manufacturing and commercialization of radiopharmaceuticals," said Ulrich Krasilnikoff, CEO of Curasight. "Today's news highlights our team as we pursue our mission to use Curasight's uPAR therapeutic program to improve cancer care through more accurate diagnosis using uTRACE with better, simpler and more effective treatment with uTREAT. Dedicated ". The primary objective of the Phase 2 Trial was to investigate Curasight's first PET tracer, 64Cu-DOTA-AE105, as a noninvasive imaging tool in prostate cancer patients followed by active surveillance. Patients on active surveillance are monitored. For changes in prostate cancer severity and can be followed for years without confirming the need for treatment.

 Trial design was informed by preliminary uTRACE studies and studies, including protocol discussions with the US Food and Drug Administration (FDA). .The Phase 2 trial is part of an approved development framework under an agreement with Curium.